Comparison of kaolin and tissue factor activated thromboelastography in haemophilia

Haemophilia

Volumn 16, Issue 3, 2010, Pages 518-524

  Young, G ^a   Zhang, R ^a   Miller, R ^a   Yassin, D ^b   Nugent, D J ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

Author keywords

Haemophilia; Inhibitors; Recombinant factor VIIa; Thromboelastography

Indexed keywords

KAOLIN; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADULT; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DILUTION; DRUG EFFECT; HEMOPHILIA; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; THROMBOELASTOGRAPHY;

ADOLESCENT; ADULT; BLOOD COAGULATION; DRUG INTERACTIONS; FACTOR VIIA; FACTOR VIII; HEMOPHILIA A; HUMANS; KAOLIN; MALE; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY; YOUNG ADULT;

EID: 77953577635     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02165.x     Document Type: Article

References (14)

1. Collins PW, Blanchette VS, Fischer K. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe haemophilia A. J Thromb Haemost 2009, 7:413-20.
2. Young G. New approaches in the management of inhibitor patients. Acta Haematol 2006, 115:172-9.
3. Hedner U. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies. Thromb Haemost 2008, 100:557-62.
4. Konkle BA, Ebbesen LS, Erhardtsen E. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007, 5:1904-13.
5. Shima M, Matsumoto T, Ogiwara K. New assays for monitoring haemophilia treatment. Haemophilia 2008, 14(Suppl 3):83-92.
6. Salooja N, Perry DJ. Thromboelastography. Blood Coagul Fibrinolysis 2001, 12:327-37.
7. Sorensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thromboelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003, 1:551-8.
8. Trowbridge CC, Stammers AH, Cicarelli N, Klayman M. Dose titration of recombinant factor VIIa using thromboelastograph monitoring in a child with haemophilia and high titer inhibitors to factor VIII: a case report and brief review. J Extra Corpor Technol 2006, 38:254-9.
9. Sorensen B, Ingerslev J. Whole blood clot formation phenotypes in haemophilia A and rare coagulation disorders. Patterns of response to rFVIIa. J Thromb Haemost 2004, 2:102-10.
10. Young G, Blain R, Nakagawa P, Nugent DJ. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia 2006, 12:598-604.
11. Young G, Ebbesen LS, Viuff D. Evaluation of thormboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagul Fibrinolysis 2008, 19:276-82.
12. Young G, Yonekawa KE, Nakagawa PA, Lovejoy AE, Blain RC, Nugent DJ. Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation. Blood Coagul Fibrinolysis 2007, 18:97-103.
13. Johansson PI, Bochsen L, Andersen S, Viuff D. Investigation of the effect of kaolin and tissue-factor activated citrated whole blood, on clot forming variables, as evaluated by thromboelastography. Transfusion 2008, 48:2377-83.
14. Wasowicz M, Srinivas C, Meineri M, Banks B, McCluskey SA, Karkouti K. Technical report: analysis of citrated blood with thromboelastography: comparison with fresh blood samples. Can J Anaesth 2008, 55:284-9.